

Effects of trichostatin A on HIF-1 α and VEGF expression in human tongue squamous cell carcinoma cells *in vitro*

FEI-WU KANG, LIN QUE, MIN WU, ZUO-LIN WANG and JING SUN

Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Tongji University, Shanghai 200072, P.R. China

Received December 28, 2011; Accepted February 17, 2012

DOI: 10.3892/or.2012.1784

Abstract. Hypoxia is an essential feature of the microenvironment of solid tumors, which regulates a variety of transcription factors including hypoxia-inducible factor-1 α (HIF-1 α). HIF-1 α overexpression enhances tumor angiogenesis via upregulation of vascular endothelial growth factor (VEGF) and some other hypoxia-inducible angiogenic factors, which lead to a more aggressive tumor phenotype, tumor metastasis and resistance to radiation and chemotherapy. In this study, we found that a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), inhibited cell proliferation and invasion, blocked the cell cycle, and induced cell apoptosis in a dose- and time-dependent manner in the human tongue squamous cell carcinoma (TSCC) SCC-6 cell line *in vitro*. Furthermore, TSA reduced both basal levels and hypoxia-induced HIF-1 α protein accumulation but not HIF-1 α mRNA levels, and both protein and mRNA levels of VEGF expression. These results showed that TSA had a potent anticancer activity on TSCC cells, suggesting that TSA could be a promising drug targeting tumor angiogenesis via inhibition of HIF-1 α and VEGF expression in the development of an effective chemopreventive and anticancer agent on human TSCCs.

Introduction

Oxygen is essential for the cells and tissues in maintaining their function and integrity. Lack of oxygen often occurs in the central area of solid tumors as well as in embryonic development (1-3), which leads to a more aggressive tumor phenotypes, characterized by abnormal angiogenesis, invasion, metastasis and resistance to radiation and chemotherapy (4,5). Angiogenesis not only has strong implications in homeostasis, but also plays an integral role in solid tumor survival, progression and metastasis (6). Hypoxia regulates a number of different transcription

factors that may be vital in hypoxia-induced cell responses including hypoxia-inducible factor (HIF-1), which regulates hypoxia-inducible angiogenic factors such as vascular endothelial growth factor (VEGF) and the glycolytic enzymes (1,7). VEGF is a survival factor in endothelial and tumor cells via VEGF receptors which are upregulated by hypoxia (8-11). This stimulates the cell to adapt to hypoxic microenvironment. Thus, enhancement of angiogenesis by hypoxia is a prerequisite for progressive growth and metastasis of solid tumors (12).

Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor consisting of two subunits: HIF-1 α and HIF-1 β . HIF-1 α is ubiquitously found in human tissues undergoing rapid ubiquitination and proteasomal degradation under normoxic conditions and stabilizes under hypoxic conditions. The expression of HIF-1 α is strictly regulated by low oxygen tension. HIF-1 α is also responsible for cell adaptation to both normoxic and hypoxic conditions. The mRNA and protein levels of HIF-1 β , also called aryl hydrocarbon receptor nuclear translocator (ARNT) (13) express constantly and are not connected with oxygen tension (14). Under normoxic conditions, the oxygen-dependent degradation domain (ODDD) of HIF-1 α interacts with the von Hippel-Lindau protein (pVHL) ubiquitin E3 ligase complex. Such HIF-1 α /von Hippel-Lindau protein interaction requires oxygen and iron-dependent hydroxylation of proline residues (Pro402 and Pro564) in HIF-1 α protein and inhibits the binding of transcriptional co-activators p300 and CBP of HIF-1 α protein via the 26S proteasome (15-20).

Under hypoxic conditions, HIF-1 α protein accumulates and stabilizes by remaining unhydroxylated, and translocates into the nucleus where it dimerizes with HIF-1 β and forms an active complex (21). The formed complex initiates transcriptional activation of its target genes via binding to hypoxia response element (HRE) located in the promoter and enhancer regions (14,22). These target genes include erythropoiesis, glycolysis (short-term solution) and angiogenesis (long-term solution) (23) which are essential for adaptation and survival under hypoxic conditions. Previous clinical research reported that overexpression of HIF-1 α has been observed in many human tumors including breast, prostate, brain, lung, tongue and their metastases, and is closely related to tumor angiogenesis, progression and invasion, and resistance to radiation and chemotherapy.

Histone acetyltransferases (HAT) and histone deacetylases (HDAC), which has been considered as transcriptional coactivator and corepressor, play vital roles in regulation of

Correspondence to: Professor Zuo Lin Wang, Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Tongji University, Shanghai 200072, P.R. China
E-mail: zuolin@mail.tongji.edu.cn

Key words: tongue squamous cell carcinoma, hypoxia-inducible factor-1 α , trichostatin A, angiogenesis

gene transcription in many cell types (24). HDAC controls gene expression, transport ubiquitinated protein aggregates, and deacetylate proteins (25-27). Inhibition of HDAC activity generally blocks the cell cycle and may affect cell proliferation and apoptosis (28,29) which is closely connected with tumorigenesis and tumor progression. Some specific HDAC inhibitors have been used to elucidate HDAC function and are suggested as a therapy for some types of cancer (30) which makes HDAC a promising target of anti-cancer activity. We investigated a specific HDAC inhibitor, trichostatin A (TSA), which was reported to be able to block cell cycle at G₁ and G₂/M phase, to inhibit cell proliferation and apoptosis in several tumor cell lines and greatly suppress tumor angiogenesis both *in vitro* and *in vivo* (12), had the same effect on human TSCC SCC-6 cells in dose- and time-dependent manner. Furthermore, we demonstrated that TSA inhibited both basal level and hypoxia-induced HIF-1 α protein accumulation and VEGF expression *in vitro*, providing further evidence that TSA could be a potential anticancer agent on human TSCC by targeting the well-known tumor survival factor HIF-1 α and its downstream gene VEGF, under hypoxia.

Materials and methods

Reagents and antibodies. Trichostatin A (TSA) was purchased from Sigma (St. Louis, MO, USA) and dissolved at a concentration of 3 mmol/l in dehydrated alcohol as a stock solution, stored at -20°C. Deferoxamine mesylate (DFX) was purchased from Sigma and dissolved in normal saline water at 50 mg/ml as a stock solution, stored at -20°C. Antibodies for HIF-1 α and VEGF were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), stored at 4°C.

Cell line and cell culture. Human tongue squamous cell carcinoma SCC-6 cell lines were provided by Dr Huang Xin, Beijing Stomatological Hospital, Capital Medical University, Beijing, China. SCC-6 cells were cultured in Dulbecco's modified Eagle's medium/F12 (DMEM/F12=1:1) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin. The cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂. To simulate hypoxic conditions, cells were treated with the hypoxia mimetic compound DFX (150 μ mol/l) instead of cultured at 5% CO₂ with 1% O₂ balanced with N₂ (31,32).

Cell proliferation assay. SCC-6 cells were plated in 96-well plates (1x10⁴/well) and treated with different concentrations of TSA (0, 200, 400, 800, 1600, 3200 nmol/l) at indicated time intervals (0, 12, 24, 48 h), and equivalent dehydrated alcohol for control groups. Then cell proliferation was analyzed by MTT colorimetric assay which determines viable cells by detecting conversion of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to a purple formazan product (33). The cells were incubated with MTT solution (1 mg/ml in DMEM/F12) for 4 h at 37°C and carefully observed to exclude crystal formation outside the cells. Then the medium was decanted, and dimethyl sulphoxide (DMSO, 150 μ l/well) added to dissolve the formazan crystals. The number of viable cells correlated with the absorbance (optical density, OD) was measured at 490 nm by Synergy 2 (BioTek). Cell viability equals the difference of




Figure 1. The proliferation inhibition of SCC-6 cells induced by TSA at the indicated concentrations and time. SCC-6 cells were cultured under different concentrations of TSA for 12, 24, 48 h, dehydrated alcohol was used as control groups. Cell proliferation was analyzed by MTT colorimetric assay. Absorbance was measured at 490 nm (bars, \pm SD, * p <0.05, ** p <0.01, # p >0.05, compared to control groups).

OD_{experiment} minus OD_{blank} divided by the difference of OD_{control} minus OD_{blank}. Each experiment was performed in triplicate and repeated three times.

Cell apoptosis. SCC-6 cells were treated with TSA at the above concentrations for 6, 12, 24 h. After harvested, the cells were washed twice with PBS and resuspended in binding buffer. Then incubated for 15 min with 5 μ l of Annexin V-FITC antibody and 10 μ l of propidium iodide (50 mg/ml) at room temperature in the dark according to the manufacturer's protocol prior to FACS analysis. Both early and late stages of apoptotic SCC-6 cells induced by TSA were detected by a flow cytometer. The presence of apoptotic cells was scored by monitoring the loss of cell membrane phospholipid asymmetry, resulting in the externalization of phosphatidylserine to the outer membrane without loss of membrane integrity (34).

Cell cycle analysis. SCC-6 cells were plated in 6-well plates (1x10⁶/well) after reaching 80% confluence, 12 h later cells were treated with different concentrations of TSA (0, 50, 100, 200, 400, 800 nmol/l), then incubated for 24 h. Cells were washed in ice-cold PBS and harvested by trypsinization. Centrifuged at 1000 rpm for 5 min, the supernatant was discarded, propidium iodide (10 μ g/ml) was added supplemented with RNaseA (200 μ g/ml) to the cells for 30 min at 37°C in the dark, then analysed by a flow cytometer of FACSCanto™ II (B&D, USA).

Cell invasion assay. After reaching 80% confluence, the SCC-6 cells (1x10⁵) were trypsinized and resuspended in the inner chamber of the insert in 200 μ l of serum-free DMEM/F12 medium. DMEM/F12 medium (500 μ l) with or without 10% FBS was added to the lower chamber. Between two chambers was the matrigel gel (B&D) diluted by serum-free DMEM/F12 medium and placed on the surface of filtration membrane of the Transwell micropore with an aperture of 8 μ m. TSA at different concentrations (0, 50, 100, 200, 400, 800 nmol/l) was added to the inner chamber and equivalent dehydrated alcohol as a control. After incubated at 37°C for 24 h, the medium non-invading cells and the extracellular matrigel gel were gently removed by a cotton-tipped swab, and the layer of invasive cells gently washed by PBS. The number of invasive cells that migrated through the gel insert to the lower surface of the membrane were stained and photographed. Results




Figure 2. The apoptosis rate of SCC-6 cells induced by TSA in indicated concentration. (A) SCC-6 cells treated with TSA in indicated concentration for 24 h. Annexin V-FITC and PI-staining of SCC-6 cells were performed and followed by flow cytometric analysis. Cells in Q1 quadrant represent cells undergoing necrosis, Q2 quadrant represent late stage of apoptosis, Q3 quadrant represent viable cells and Q4 quadrant represent early stage of apoptosis. (B) TSA increased the SCC-6 cell apoptosis rate (early stage) in a dose- and time-dependent manner (bars, \pm SD, * p <0.05, ** p <0.01, compared to control group).

were presented as the mean percentage of the control (control OD at 562 nm assigned as 100%). Experiments were done in triplicate and repeated three times.

Real-time reverse transcription polymerase chain reaction (real-time PCR). SCC-6 cells were treated with varied concentrations of DFX or/and TSA at different time periods, respectively. Total RNA was prepared using TRIzol reagent (Invitrogen, USA), and cDNA was synthesized by PrimeScript[®] RT reagent kit (Takara, China). HIF-1 α and VEGF mRNA expression was evaluated quantitatively by real-time RT-PCR with SYBR[®] Premix Ex Taq[™] (Takara) and ABI PRISM 7900HT real-time PCR system (35). The thermocycler conditions were preheating at 95°C for 30 sec, cycles of 95°C for 5 sec, 60°C for 30 sec. The relative amount of PCR product was evaluated as threshold cycle (CT value) of the sample divided by that of β -actin. All experiments were done in triplicate and repeated three times. The primers were synthesized (Sangon, China) and the sequences were: HIF-1 α : forward 5'-GAA CCTGATGCTTTAAACT-3', reverse 5'-CAACTGATCGAAGGAACG-3'; VEGF: forward 5'-TTTCTGCTGTCTTGG GTGCATTGG-3', reverse 5'-TCTGCATGGTGATGTTGGA CTCCT-3'; β -actin: forward 5'-TGGCACCCAGCACAAT

GAA-3', reverse 5'-CTAAGTCATAGTCCGCCTAGAA GCA-3'.

Western blot analysis. After SCC-6 cells were treated with varied concentrations of DFX or/and TSA at different time periods. Cells were washed with ice-cold PBS twice and treated with buffer (50 mmol/l Tris-HCl (pH 7.5), 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5% Triton X-100, 10 mmol/l sodium fluoride, 20 mmol/l β -mercaptoethanol, 250 μ mol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride 50 mmol/l Tris-HCl (pH 7.5), 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5% Triton X-100, 10 mmol/l sodium fluoride, 20 mmol/l β -mercaptoethanol, 250 μ mol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride). The lysates were centrifuged at 1000 rpm for 10 min and the supernatants were collected and stored at -80°C. Protein concentrations were determined by bicinchoninic acid assay methods (BCA protein assay kit, Thermo, USA). Equivalent amount of protein (40 μ g) were loaded into 8-12% SDS-PAGE gel and electroblotted onto protein nitrocellulose membrane (Sigma). The NC membrane was rinsed in PBS-T solution (0.1% Tween-20 in PBS, pH 7.5) and blocked with 5% skim milk in PBS-T at room temperature. The membrane was incubated with HIF-1 α (1:200) and VEGF (1:500) antibody overnight at 4°C and washed with PBS-T four times every 10 min, then incubated with secondary antibody against rabbit (HIF-1 α) and mouse (VEGF) (1:2000) at room temperature for 1 h and washed with PBS-T four times every 10 min (36,37). The signals were visualized by enhanced chemiluminescence using Odyssey chemiluminescence system (LI-COR, USA).

Statistical analysis. Statistical analysis was performed using the SPSS 14.0 software package. Data were expressed as the means \pm SD. A paired Student's test was used for statistical analysis, with significant differences determined as p <0.05.

Results

TSA inhibited cell proliferation of SCC-6 cells. SCC-6 cells were treated with different concentrations of TSA for 12, 24, 48 h, dehydrated alcohol was used as control group. Within 12 h, the proliferation of SCC-6 cells treated with 200, 400, 800 nmol/l of TSA was not inhibited significantly compared to the control group (94.48 \pm 0.21%, 90.10 \pm 0.51%, 90.28 \pm 0.01% vs. 99.12 \pm 0.11%, p >0.05) until the concentration of TSA reached 1600, 3200 nmol/l (86.06 \pm 3.43%, 84.64 \pm 4.87% vs. 99.12 \pm 0.11%, p <0.05). At 24 and 48 h, TSA significantly inhibited the proliferation of SCC-6 cells compared to control groups even at 200 nmol/l (0.7927 \pm 0.0131 vs. 0.9901 \pm 0.0013, 0.7427 \pm 0.0257 vs. 0.9166 \pm 0.0021, P <0.01) (Fig. 1). These results suggest that TSA inhibited the proliferation of SCC-6 cells in a dose- and time-dependent manner.

Apoptosis of SCC-6 cells induced by TSA. After SCC-6 cells were treated with different concentrations of TSA for 6, 12, 24 h, apoptosis rate of SCC-6 cells increased significantly in a concentration-dependent manner, compared to control groups, especially at 24 h (6.17 \pm 0.92%, 10.64 \pm 1.87%, 21.92 \pm 2.73% vs. 3.31 \pm 0.45%, p <0.05; 42.15 \pm 4.17%, 44.56 \pm 4.66% vs. 3.31 \pm 0.45%, p <0.01) (Fig. 2), indicating that TSA induced cell apoptosis of SCC-6 cells in a dose- and time-dependent




Figure 3. The cell cycle changes of SCC-6 cells treated with TSA at indicated concentrations for 24 h. The cell cycle was analysed by flow cytometry using propidium iodide for DNA staining. Percentage of cell numbers decreased at G₀/G₁ phase and increased at S and G₂/M phase.

manner, and this effect might be related to the cell cycle blockade at S and G₂/M phase.

Effect of TSA on cell cycle of SCC-6 Cells. SCC-6 cells were treated with different concentrations of TSA for 24 h, then DNA staining by propidium iodide was done for discrimination of cells at G₀/G₁ phase or S and G₂/M phase by FACS. With the concentrations of TSA increased, the cells at G₀/G₁ phase decreased significantly (50.06 \pm 4.27%, 47.68 \pm 5.24%, 53.53 \pm 6.27%, 42.19 \pm 5.39%, 39.38 \pm 4.86% vs. 65.26 \pm 4.47%, p <0.05). Consequently, the cells at G₂/M and S phase significantly increased, respectively (15.63 \pm 1.78%, 17.76 \pm 2.01%, 38.57 \pm 4.24%, 44.33 \pm 5.19%, 45.16 \pm 4.83% vs. 17.09 \pm 1.28%, p <0.05) (34.31 \pm 3.97%, 34.64 \pm 4.26%, 7.90 \pm 0.97%, 13.48 \pm 1.47%, 15.46 \pm 1.84% vs. 17.66 \pm 1.24%, p <0.05) (Fig. 3). Thus, TSA blocked the cell cycle of SCC-6 cells at S and G₂/M phase.

Cell invasion inhibited by TSA of SCC-6 cells. A previous study had shown the possible function of HIF-1 α in the regulation of colon carcinoma cell invasion (38). To investigate TSA cancer cell invasion of SCC-6 cells *in vitro*, we applied the transwell assay. After SCC-6 cells were treated with indicated concentrations of TSA, incubated in the transwell chamber for 24 h, viola crystalline staining was used to discriminate the cells passing

through the matrigel membrane which represent the invasive abilities of SCC-6 cells (Fig. 4A). As shown (Fig. 4B), with the concentrations of TSA increased, the number of SCC-6 cells passing through the matrigel membrane significantly decreased and the inhibition rate of cell invasion increased (12.27 \pm 1.84%, 30.67 \pm 4.91%, 41.10 \pm 4.29%, p <0.05, 62.27 \pm 2.76%, 74.4 \pm 2.75% vs. 0.00 \pm 4.29%, p <0.01).

Expression of HIF-1 α and VEGF induced by hypoxia. Hypoxia, a common microenvironment in aggressive solid tumors regulating many transcriptional factors including HIF-1 α , which controls hypoxia-inducible angiogenic factors such as VEGF (39). As shown (Fig. 5A and C), under normoxia, control or mimic hypoxia (DFX 150 nmol/l) groups, no significant change in HIF-1 α mRNA transcript was observed (p >0.05, Fig. 5E); basal level of VEGF mRNA expression was observed under normoxia and it became more obviously under mimic hypoxia (p <0.05, Fig. 5E) which increased with time and was significantly expressed at 24 h (Fig. 5C). Western blot assay demonstrated that hypoxia induced rapid and sustained HIF-1 α and VEGF protein accumulation in SCC-6 cells in a time-dependent manner which was significant up to 24 h (Fig. 5B and D). These data prove the instability of HIF-1 α under normoxic conditions and that it stabilizes under hypoxic conditions, which suggests the hypoxic regulation of HIF-1 α is at the protein level. The expression of mRNA and protein levels of VEGF, a direct downstream gene of HIF-1 α , increases significantly as the activity of HIF-1 α increases.

TSA inhibited hypoxia-induced accumulation of HIF-1 α protein and VEGF expression under hypoxic conditions. As shown (Fig. 6A), no apparent changes in HIF-1 α mRNA were observed in SCC-6 cells after exposed to hypoxia and TSA (800 nmol/l) for 24 h, and different concentrations and time intervals of TSA also had no effect on HIF-1 α mRNA expression by RT-PCR (Fig. 6C, E and G). The results of western blotting showed a low but detectable and steady-state basal level of HIF-1 α protein expression under normoxia and increasing significantly under hypoxia (Figs. 5B and 6B). To investigate the temporal effects of TSA on baseline of HIF-1 α protein expression, we treated SCC-6 cells with 800 nmol/l TSA under normoxic and found that basal level of HIF-1 α protein expression was reduced to




Figure 4. The effect of TSA on cell invasion of SCC-6 cells for 24 h at indicated concentrations. (A) The tiny tubercle micropores on the Matrigel basement membrane of transwell chambers and the staining cells represent the invasive abilities of SCC-6 cells (Viola crystalline staining, \times 40). (B) TSA inhibited cell invasion of SCC-6 cells in a concentration-dependent manner (bars, \pm SD, * p <0.05, ** p <0.01, compared to control group).




Figure 5. Mimic hypoxia induces HIF-1α protein accumulation and VEGF expression. (A) The mRNA expression of HIF-1α and VEGF by RT-PCR. SCC-6 cells were cultured under normoxia, control groups (normal saline water in which DFX dissolves) or DFX (150 nmol/l) for 24 h. (B) The protein level of HIF-1α and VEGF expression by western blot under normoxia, control groups or DFX (150 nmol/l) for 24 h. (C) The mRNA level of HIF-1α and VEGF expression under mimic hypoxia in indicated time intervals. SCC-6 cells were exposed to DFX (150 nmol/l) for 6, 12, 24 or 48 h. (D) The protein level of HIF-1α and VEGF expression under mimic hypoxia in indicated time intervals. (E) The quantitative analysis of HIF-1α and VEGF mRNA expression under normoxia, control groups or DFX (150 nmol/l) for 24 h, evaluated as sample threshold cycle (CT) value divided by β-actin CT value (bars, ±SD, *p<0.05, #p>0.05, compared to Normoxia groups).

low or undetectable (Fig. 6B). To explore whether TSA could also inhibit hypoxia-induced HIF-1α protein expression, SCC-6 cells were treated with different concentrations and time intervals of TSA under hypoxia, the results showed that TSA inhibited hypoxia-induced HIF-1α protein accumulation in a concentration and time-dependent manner (Fig. 6D and F). Markedly, this inhibitory effect was not due to a decrease in its mRNA level, suggesting that TSA inhibited hypoxia-induced HIF-1α protein accumulation through a post-transcriptional mechanism.

VEGF, an immediate downstream target gene of HIF-1α, plays a pivotal role in tumor angiogenesis under conditions of intratumoral hypoxia (23,40). To explore whether TSA could inhibit hypoxia-induced VEGF expression, we examined VEGF expression by RT-PCR and western blotting. The results showed an obvious decrease of VEGF mRNA and protein level expression after SCC-6 cells were treated with TSA at both basal and hypoxia-induced level (Fig. 6A, B and G). To further confirm the effects of TSA on VEGF expression, SCC-6 cells were treated with different concentrations and time intervals of TSA under hypoxia. Our results indicated that the robust increase in VEGF mRNA and protein level expression induced by hypoxia was significantly suppressed by TSA in a dose- and time-dependent manner (Fig. 6C-F). Together, these data suggested that TSA inhibited hypoxia-induced angiogenesis through concurrent suppression of HIF-1α and VEGF. The




Figure 6. TSA inhibits both basal level and hypoxia induced HIF-1α protein accumulation and VEGF expression under hypoxic conditions. (A) The effect of TSA on mRNA level of HIF-1α and VEGF expression by RT-PCR. SCC-6 cells were cultured under normoxia, DFX (150 nmol/l), TSA (800 nmol/l) or DFX (150 nmol/l) and TSA (800 nmol/l) for 12 h, respectively. (B) The effect of TSA on protein level of HIF-1α and VEGF expression by western blotting. (C) The effect of TSA at indicated time intervals on mRNA level of HIF-1α and VEGF expression under hypoxic conditions. SCC-6 cells were exposed to DFX (150 nmol/l) for 24 h, then treated with TSA (800 nmol/l) for 3, 6, 12, 24 h. (D) The effect of TSA at indicated time intervals on protein level of HIF-1α and VEGF expression under hypoxic conditions. (E) Indicated concentrations of TSA on mRNA level of HIF-1α and VEGF expression under hypoxic conditions. SCC-6 cells were exposed to DFX (150 nmol/l) for 24 h, then treated with TSA at 50, 100, 200, 400, 800 nmol/l for 12 h. (F) Indicated concentrations of TSA on protein level of HIF-1α and VEGF expression under hypoxic conditions. (G) The quantitative analysis of HIF-1α and VEGF mRNA expression under normoxia, DFX (150 nmol/l), TSA (800 nmol/l) or DFX (150 nmol/l) and TSA (800 nmol/l) for 24 or 12 h, respectively, evaluated as sample threshold cycle (CT) value divided by β-actin CT value (bars, ±SD, *p<0.05, **p<0.01, #p>0.05, DFX compared to Normoxia groups, DFX and TSA compared to DFX groups).

viability of SCC-6 cells showed no apparent changes in cell morphology or toxicity at the above concentrations of TSA for 12 h (Fig. 1), indicating that this inhibitory effect by TSA was not ascribed to nonspecific tumor cell toxicity.

Discussion

Histone deacetylation and acetylation is considered as a key regulatory mechanism of gene transcription. Histone deacetylases (HDACs) act to oppose the activity of histone

acetyltransferases (HATs). The dysfunction of HDACs and HATs may lead to tumorigenesis which has been confirmed in leukemia (41). Past research demonstrated that HDAC inhibitor exerts anticancer activity via suppression of HDAC activity, induction of histone acetylation and regulation of gene transcription (42,43). Recently, specific HDAC inhibitors such as LAQ824, FK228, sodium butyrate, resveratrol and trichostatin A have been reported to inhibit tumor growth, survival, metastasis and downregulate HIF-1 α stability in many cancer cell lines (44-48). HIF-1 α , regulated by hypoxia, transactivates many target genes encoding proteins related to tumor angiogenesis, regulation of blood vessel tone, and vascular remodelling by HIF-1 α mediated overexpression of VEGF and NO; cell proliferation and viability by IGF-2; erythropoiesis and iron metabolism by EPO; glucose transport and glycolysis by GLUT-1,3, which makes HIF-1 α a key transcriptional factor in tumor cell survival (13).

In this study, we adopted a potent HDAC inhibitor, trichostatin A (TSA), with anticancer activity. It was first reported to induce cell differentiation in mice leukemia cells by Yoashi in 1987 (49), demonstrated to inhibit tumor cell proliferation, block cell cycle, induce cell apoptosis and differentiation, block tumor angiogenesis *in vitro* and *in vivo*, via upregulating p53 and VHL expression and downregulating HIF-1 α and VEGF (12,50). TSA significantly inhibited cell proliferation of SCC-6 cells *in vitro* in a dose- and time-dependent manner (Fig. 1) which was partially related to TSA-induced cell apoptosis with the same dose- and time-dependent manner (Fig. 2). HIF-1 α was the key regulator to cellular adaptation under hypoxia, at the same time, endoplasmic reticulum (ER) stress could be induced and resulted in inhibition of protein translation, which could induce the cells to enter the cell cycle, leading to mitogenic responses. Therefore, the proliferation of SCC-6 cells may be an integrated stress response involving an ER-generated signal and the cellular adaptation to hypoxia (51).

HIF-1 α regulates target genes directly or indirectly relating to cell apoptosis, some of which play a dual role in regulating apoptosis of tumor cells, which makes HIF-1 α both anti-apoptotic and pro-apoptotic. It is the oxygen tension that considered to determine whether HIF-1 α function as anti-apoptotic or pro-apoptotic. Blagosklonny *et al* reported that the stabilization of p53 protein depend on HIF-1 α , resulting in the induction of apoptosis under hypoxia (52). However, another study showed that HIF-1 α might have a protective role in limiting hypoxia-induced apoptosis via suppression of caspase-3 activity (53). There is a cell cycle specificity in some type of cell apoptosis, acting as different inducements in cell apoptosis at different cell cycle phases. Cell apoptosis occurs after cell cycle blockade at a certain phase (54,55). To investigate whether the TSA-induced cell apoptosis of SCC-6 cells is cell cycle specific, we analyzed cell cycles of SCC-6 cells after treated with TSA by FCM. The percentage of cells at G₂/M phase increased and cells at G₀/G₁ phase decreased as the concentration of TSA increased, which agreed with the change of cell apoptosis rate (Fig. 3). Thus, we presume the TSA-induced cell apoptosis of SCC-6 cells is relevant to its cell cycle blockade at G₂/M phase.

Cell invasion, involved in tumor metastasis and progression, is known to be upregulated by hypoxia, through hypoxia-induced expression of matrix metalloproteases (MMPs) and

inhibition of E-cadherin and β -catenin. The present study analyzed the effect on cell invasion of SCC-6 cells by TSA applying a transwell assay *in vitro*. Results showed that after treated with different concentrations of TSA, cell numbers that passed through the extracellular matrices (ECM) reduced significantly and inversely correlated with the TSA concentrations (Fig. 4). Thus, TSA inhibits cell invasion of SCC-6 cells *in vitro* in a dose-dependent manner.

HIF-1 α is hydroxylated, acetylated and bound by the von Hippel-Lindau (pVHL) ubiquitin E3 ligase complex under normoxia, leading to HIF-1 α polyubiquitination and proteosomal degradation. In contrast, under hypoxia, HIF-1 α hydroxylation and acetylation are suppressed by low oxygen tension, leading to stabilization of HIF-1 α , which translocates to the nucleus to bind HIF-1 β and recruit CBP/p300 resulting in gene transcription. Hypoxia also induces HDACs expression which deacetylates HIF-1 α to increase HIF-1 α transcriptional activity. Thus, HDAC inhibitor reverses the activity of HDACs resulting in the degradation of HIF-1 α (6,28,44,46). Our study demonstrated that TSA inhibited both basal level and hypoxia-induced HIF-1 α protein accumulation and VEGF mRNA and protein expression under hypoxia (Figs. 5 and 6). This significant inhibitory effect of VEGF may play a direct and critical role in the inhibition of angiogenesis under hypoxic conditions. However, to investigate whether the anti-angiogenic activity of TSA is the hypoxia-specific regulated mechanism, an *in vivo* tumor generation experiments with SCC-6 cells is needed. Only when the results of *in vivo* experiments are in accordance with the outcome of the present *in vitro* experiments can we presume that the functional HIF-1 α and its target, VEGF, play critical roles in tumor cells in the process of hypoxia-induced tumor angiogenesis.

In conclusion, our present study demonstrates that TSA, a HDAC inhibitor, function as a powerful anticancer agent *in vitro* through its potent inhibition of HIF-1 α and its downstream target gene, VEGF, under hypoxia, a common characteristic of most solid cancers. We suggest that TSA can be further investigated as a novel anticancer agent targeting tumor angiogenesis via inhibition of HIF-1 α activity and VEGF expression.

Acknowledgements

Our study was supported by the Project of Science and Technology Talents of Shanghai, Science and Technology Commission of Shanghai Municipality (Grant No. 09QA1406400). We also thank Wang Kai and Gao Yin for their excellent technical and theoretical assistance.

References

1. Guillemin K and Krasnow MA: The hypoxic response: huffing and HIFing. *Cell* 89: 9-12, 1997.
2. Ryan HE, Lo J and Johnson RS: HIF-1 α is required for solid tumor formation and embryonic vascularization. *EMBO J* 17: 3005-3015, 1998.
3. Kim KW, Bae SK, Lee OH, *et al*: Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. *Cancer Res* 58: 348-351, 1998.
4. Höckel M, Schlenger K, Mitze M, *et al*: Hypoxia and radiation response in human tumors. *Semin Radiat Oncol* 6: 3-9, 1996.
5. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J Natl Cancer Inst* 93: 266-276, 2001.

6. Ellis L, Hammers H and Pill R: Targeting tumor angiogenesis with histone deacetylase inhibitors. *Cancer Lett* 280: 145-153, 2009.
7. Wenger RH and Gassman M: Oxygen and the hypoxia-inducible factor-1. *J Biol Chem* 378: 609-616, 1997.
8. Nor JE, Christensen J, Mooney DJ, *et al*: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. *Am J Pathol* 154: 375-384, 1999.
9. Gupta K, Kshirsagar S, Li W, *et al*: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. *Exp Cell Res* 247: 495-504, 1999.
10. Baek JH, Jang JE, Kang CM, *et al*: Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. *Oncogene* 19: 4621-4631, 2000.
11. Waltenberger J, Mayr U, Pentz S, *et al*: Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. *Circulation* 94: 1647-1654, 1996.
12. Myoung SK, Kwon HJ, Lee YM, *et al*: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. *Nat Med* 7: 437-443, 2001.
13. Semenza GL: Hypoxia-inducible factor-1: master regulator of O₂ homeostasis. *Curr Opin Genet Dev* 8: 588-594, 1998.
14. Kallio PJ, Pongratz I, Gradin K, *et al*: Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. *Proc Natl Acad Sci USA* 94: 5667-5672, 1997.
15. Epstein AC, Gleadle JM, McNeill LA, *et al*: *Elegans* EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell* 107: 43-54, 2001.
16. Ivan M, Konda K, Yang H, *et al*: HIF-1alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science* 292: 464-468, 2001.
17. Jaakkola P, Mole DR, Tian YM, *et al*: Targeting of HIF-1alpha to the von Hippel-Lindau ubiquitination complex by O₂-regulated prolyl hydroxylation. *Science* 292: 468-472, 2001.
18. Salceda S and Caro J: Hypoxia-inducible factor-1alpha protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem* 272: 22642-22647, 1997.
19. Huang LE, Gu J, Schau M, *et al*: Regulation of hypoxia-inducible factor 1alpha is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci USA* 95: 7987-7992, 1998.
20. Maxwell PH, Wiesener MS, Chang GW, *et al*: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* 399: 271-275, 1999.
21. Ema M, Hirota K, Mimura J, *et al*: Molecular mechanisms of transcription activation by HLF and HIF 1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. *EMBO J* 18: 1905-1914, 1999.
22. Huang LE, Arany Z, Livingston DM and Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. *J Biol Chem* 271: 32253-32259, 1996.
23. Semenza GL: Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 3: 721-732, 1996.
24. Grunstein M: Histone acetylation in chromatin structure and transcription. *Nature* 389: 349-352, 1997.
25. Kawaguchi Y, Kovacs JJ, McLaurin A, *et al*: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* 115: 727-738, 2003.
26. Hubbert C, Guardiola A, Shao R, *et al*: HDAC6 is a microtubule-associated deacetylase. *Nature* 417: 455-458, 2002.
27. Matsuyama A, Shimazu T, Sumida Y, *et al*: *In vivo* destabilization of dynamic microtubules by HDAC6-mediated deacetylation. *EMBO J* 21: 6820-6831, 2002.
28. Kouraklis G and Theocharis S: Histone deacetylase inhibitors and anticancer therapy. *Curr Med Chem Anti-Cancer Agents* 2: 477-484, 2002.
29. Rosato RR and Grant S: Histone deacetylase inhibitors in cancer therapy. *Cancer Biol Ther* 2: 30-37, 2003.
30. Kosugi H, Towatari M, Hatano S, *et al*: Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. *Leukemia* 13: 1316-1324, 1999.
31. Balanos GM, Dorrington KL and Robbins PA: Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. *J Appl Physiol* 92: 2501-2507, 2002.
32. Ardyanto TD, Osaki M, Tokuyasu N, *et al*: CoCl₂-induced HIF-1alpha expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. *Int J Oncol* 29: 549-555, 2006.
33. Abasolo I, Wang Z, Montuenga LM, *et al*: Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP independent autocrine mechanism. *Biochem Biophys Res Commun* 322: 878-886, 2004.
34. Martin SJ, Reutlingsperger CP, McGahon AJ, *et al*: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J Exp Med* 182: 1545-1556, 1995.
35. Leong DT, Gupta A, Bai HF, *et al*: Absolute quantification of gene expression in biomaterial research using real-time PCR. *Biomaterials* 28: 203-210, 2007.
36. Lee SW, Han SI, Kim HH, *et al*: TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. *J Biochem Mol Biol* 35: 371-376, 2002.
37. Chun YS, Choi E, Kim GT, *et al*: Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1alpha. *Eur J Biochem* 267: 4198-4204, 2000.
38. Krishnamachary B, Berg-Dixon S, Kelly B, *et al*: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor-1. *Cancer Res* 63: 1138-1143, 2003.
39. Carmeliet P, Dor Y, Herbert JM, *et al*: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* 394: 485-490, 1998.
40. Shweiki D, Itin A, Soffer D, *et al*: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* 359: 843-845, 1992.
41. Fenrick R and Hiebert SW: Role of histone deacetylases in acute leukemia. *J Cell Biochem (Suppl)* 30-31: 194-202, 1998.
42. Kung AL, Wang S, Klco JM, *et al*: Suppression of tumor growth through disruption of hypoxia-inducible transcription. *Nat Med* 6: 1335-1340, 2000.
43. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. *Crit Rev Biochem Mol Biol* 35: 71-103, 2000.
44. Kwon HJ, Kim MS, Kim MJ, *et al*: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. *Int J Cancer* 97: 290-296, 2002.
45. Vigushin DM, Ali S, Pace PE, *et al*: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer *in vivo*. *Clin Cancer Res* 7: 971-976, 2001.
46. Lee YM, Kim SH, Jin Son M, *et al*: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. *Biochem Biophys Res Commun* 300: 241-244, 2003.
47. Liu LT, Chang HC, Chiang LC, *et al*: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. *Cancer Res* 63: 3069-3072, 2003.
48. Zhang QZ, Tang XD, Liu QY, *et al*: Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1A and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. *Mol Cancer Ther* 4: 1465-1473, 2005.
49. Yoshida M, Kijima M, Akita M, *et al*: Potent and specific inhibition of mammalian histone deacetylase both *in vivo* and *in vitro* by trichostatin A. *J Biol Chem* 265: 17174-17179, 1990.
50. Xiao H, Hasegawa T and Isobe K: p300 collaborates with Sp1 and Sp3 in p21(waf1/cipl) promoter activation induced by histone deacetylase inhibitor. *J Biol Chem* 275: 1371-1376, 2000.
51. Song Y, Wang WX, Qu X, *et al*: Effects of hypoxia inducible factor-1alpha on the growth and adhesion in tongue squamous cell carcinoma cells. *Indian J Med Res* 129: 154-163, 2009.
52. Blagosklonny MV, An WG, Romanova LY, *et al*: p53 inhibits hypoxia-inducible factor-stimulated transcription. *J Biol Chem* 273: 11995-11998, 1998.
53. Akakura N, Kobayashi M, Horiuchi I, *et al*: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. *Cancer Res* 61: 6548-6554, 2001.
54. Strait KA, Dabbas B, Hammond EH, *et al*: Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. *Mol Cancer Ther* 1: 1181-1190, 2002.
55. Kim YB, Ki SW, Yoshida M, *et al*: Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. *J Antibiot* 53: 1191-1200, 2000.